Sequent Scientific Limited

NSE SEQUENT.NS

Sequent Scientific Limited EBITDA Margin for the year ending March 31, 2024: 4.02%

Sequent Scientific Limited EBITDA Margin is 4.02% for the year ending March 31, 2024, a 223.10% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Sequent Scientific Limited EBITDA Margin for the year ending March 31, 2023 was -3.27%, a -138.34% change year over year.
Sequent Scientific Limited EBITDA Margin for the year ending March 31, 2022 was 8.53%, a -45.52% change year over year.
Sequent Scientific Limited EBITDA Margin for the year ending March 31, 2021 was 15.65%, a 0.68% change year over year.
Sequent Scientific Limited EBITDA Margin for the year ending March 31, 2020 was 15.55%, a 18.74% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: SEQUENT.NS

Sequent Scientific Limited

CEO	Mr. Rajaram Narayanan
IPO Date	March 10, 2016
Location	India
Headquarters	Dosti Pinnacle
Employees	1,195
Sector	Health Care
Industries Pharmaceuticals Biotechnology Pet Food

Description

Sequent Scientific Limited engages in the animal health business worldwide. The company provides animal health active pharmaceutical ingredients (APIs) and finished dosage formulations in the areas of feed supplements, antibiotics, anthelmintics, antibacterial, anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It offers analytical solutions that supports API, pharmaceutical, personal care, and nutraceutical organizations, as well as provides method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs and Pharmaceuticals Limited and changed its name to Sequent Scientific Limited in October 2009. Sequent Scientific Limited was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited operates as a subsidiary of CA Harbor Investments.

Key trends

Past 5 years